CION Ameerpet
Childhood Cancer Genetics — Parent’s Guide
Beckwith-Wiedemann syndrome & Wilms tumour / hepatoblastoma risk
Medically reviewed by Dr. C. Raghavendra Reddy, DM (Medical Oncology, Gold Medal) · Last reviewed June 2026
If your child has been diagnosed with Beckwith-Wiedemann syndrome (BWS), you may already know it raises the risk of certain childhood cancers — particularly Wilms tumour (a kidney cancer) and hepatoblastoma (a liver cancer). This page explains why that risk exists, what it means in practice, and how a structured BWS screening programme gives your child the best chance of early detection. You deserve clear answers, not just labels.
- Coordinated genetics & oncology care — genetics, paediatric oncology, and radiology working together on your child’s surveillance plan
- Tumor board for every child — no single doctor’s opinion; every case is reviewed by the full specialist team before decisions are made
- 45-minute consultations — enough time to go through every report, every scan, and every question without feeling rushed
- Free first consultation — bring your child’s genetic reports and any imaging already done; our team will review everything at no charge
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Understanding the diagnosis
What is Beckwith-Wiedemann syndrome?
Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth condition caused by a disruption in how a specific region of chromosome 11 is regulated. This region — labelled 11p15.5 by geneticists — carries genes that control how cells grow, divide, and stop growing. In BWS, this control is altered, leading to a pattern of excessive growth in certain tissues and organs.
The features of BWS vary considerably from one child to another. Some children have only one or two features; others have several. Common features include: a larger-than-average birth size and weight; a slightly enlarged tongue (macroglossia) that may affect feeding or speech; an abdominal wall opening at birth (omphalocele) or a persistent umbilical hernia; organs that are larger than normal — particularly the liver, spleen, or kidneys (organomegaly); asymmetric overgrowth where one side of the body or one limb is noticeably larger than the other (hemihyperplasia); and low blood sugar in the newborn period (neonatal hypoglycaemia), which requires prompt management.
The diagnosis of BWS is made by a clinical geneticist or a paediatrician with expertise in dysmorphology. Molecular genetic testing of the 11p15.5 region is recommended for all children suspected of having BWS, because the precise molecular change determines the level of cancer risk and guides how often surveillance scans should be performed.
What causes BWS? BWS is not caused by anything the parents did. The molecular changes that lead to BWS arise during the formation of the embryo — events that are outside any family’s control. In most cases, BWS occurs without a family history and is not inherited in the way many parents expect. In a minority of cases, there is a familial form with an autosomal dominant inheritance pattern, which a genetic counsellor can explain clearly in your family’s context.
The most important thing to understand about BWS and cancer risk is this: the same growth-regulation problem that causes the physical features of BWS is also the reason why certain childhood tumours are more likely to develop. Recognising this link — and acting on it with a structured surveillance programme — is the most powerful tool available to protect your child.
Understanding cancer risk in BWS
Why BWS raises cancer risk — and which cancers to watch for
The same chromosome 11 growth-regulation disruption that defines BWS is also the biological driver of its cancer risk. Understanding which tumours are associated with BWS — and why — helps parents engage meaningfully with the surveillance plan their child’s team proposes.
Primary risk
Wilms tumour (nephroblastoma) — the kidney cancer linked to BWS
Wilms tumour is the most common cancer associated with BWS. It arises in the kidney from abnormal clusters of primitive kidney cells called nephrogenic rests — cells that failed to mature normally and can, over time, grow into tumours. Because the chromosome 11 genes that regulate kidney cell growth are disrupted in BWS, these abnormal rests are more likely to be present. Most Wilms tumours in BWS children are diagnosed before the age of seven or eight, which is why abdominal ultrasound surveillance is continued well into the primary school years. Early detection at a small, localised stage means that kidney-sparing treatment is far more likely to be successful.
- Regular ultrasound is the primary tool for early detection
- Most BWS-related Wilms tumours are unilateral (one kidney), but bilateral cases do occur
- Children with certain BWS molecular subtypes have a higher Wilms tumour risk than others
Primary risk
Hepatoblastoma — the liver cancer linked to BWS
Hepatoblastoma is a cancer that arises in the liver, and BWS is one of the best-established risk factors for this tumour in young children. The connection again lies in the 11p15.5 region: the same growth-dysregulation that drives the hepatomegaly (enlarged liver) seen in some BWS infants also creates a cellular environment in which hepatoblastoma can develop. Hepatoblastoma occurs predominantly in infants and children under the age of four, which is why surveillance for this tumour is most intensive during the first three to four years of life. Serum alpha-fetoprotein (AFP) — a protein produced by hepatoblastoma cells — is measured at regular intervals alongside ultrasound as part of the surveillance plan.
- Risk is highest in the first three to four years of life
- AFP blood test supplements abdominal ultrasound in hepatoblastoma surveillance
- A rising AFP level can prompt earlier imaging even between scheduled scans
Less common
Other tumours reported in BWS
While Wilms tumour and hepatoblastoma account for the large majority of tumours seen in BWS children, other cancers have been reported in smaller numbers. These include adrenocortical carcinoma (a rare cancer of the adrenal gland), rhabdomyosarcoma (a muscle tumour), and certain other embryonal tumours. These associations are less common and less precisely quantified than the Wilms tumour and hepatoblastoma risk. Knowing that they can occur reinforces the importance of not ignoring unexplained symptoms — a new lump, unexplained weight loss, persistent abdominal pain, or blood in the urine — even between scheduled surveillance appointments.
- Any new unexplained symptom in a child with BWS warrants prompt paediatric assessment
- Surveillance programmes may be adapted over time as evidence evolves
- Adrenocortical carcinoma may present with signs of hormonal excess (early puberty signs, unusual growth)
Hemihyperplasia
Isolated hemihyperplasia — a related risk condition
Some children have isolated hemihyperplasia — asymmetric body growth — without meeting the full clinical criteria for BWS. Hemihyperplasia can occur as part of BWS, or it can be present on its own. In both situations, it is considered a marker of chromosome 11p15 dysregulation and is associated with a similar pattern of cancer risk: primarily Wilms tumour and hepatoblastoma. Children with isolated hemihyperplasia who have undergone genetic testing and show 11p15 changes should be enrolled in the same surveillance protocol as children with confirmed BWS. If your child has been told they have hemihyperplasia but has not yet had molecular testing or seen a genetics team, a referral is appropriate.
- Hemihyperplasia shares the BWS cancer risk profile when linked to 11p15 changes
- Surveillance protocol mirrors that for BWS
- Referral to clinical genetics is strongly recommended for all children with hemihyperplasia
Learn more about Wilms tumour in our bilateral Wilms tumour guide, or return to the pediatric cancer hub for the full range of childhood cancer topics.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your child’s screening should not wait
We walk this journey with you — from confirming the right surveillance protocol to being available when a scan result raises a question. Decisions for healing, not billing.
BWS screening child — what to expect
BWS cancer surveillance — how screening actually works
Cancer surveillance in a child with Beckwith-Wiedemann syndrome is a structured, multi-year programme — not a single scan. Understanding what each step involves helps parents prepare, ask the right questions, and stay calm between appointments.
Confirm the molecular subtype — this determines your child’s risk level
Before a surveillance protocol can be finalised, the clinical genetics team needs to establish exactly which molecular change underlies your child’s BWS. The chromosome 11p15.5 region can be disrupted in several different ways — through epigenetic (methylation) changes at one of two control centres (H19/ICR1 or KCNQ1OT1/ICR2), through paternal uniparental disomy (pUPD11), through structural changes in the chromosome, or through mutations in specific genes within this region. Each molecular subtype carries a somewhat different profile of cancer risk. Knowing the subtype means the surveillance plan is tailored to your child, not a generic average. If genetic testing has not been done yet, this is the first step.
Begin abdominal ultrasound surveillance — from as early as the first weeks of life
Abdominal ultrasound is the primary surveillance tool for both Wilms tumour and hepatoblastoma. It is safe, involves no radiation, and can detect small tumours in the kidneys and liver before they cause any symptoms. Published surveillance guidelines recommend starting scans early — ideally from the first months of life for children with confirmed BWS — and continuing them at intervals of approximately every three to four months throughout the period of highest risk. The scans are generally performed by a paediatric radiologist familiar with what early tumours look like in this context, and results should be reviewed by an oncology team, not interpreted in isolation.
Monitor AFP levels for hepatoblastoma risk — alongside the ultrasound programme
Serum alpha-fetoprotein (AFP) is a protein that is naturally elevated in newborns and falls to adult levels over the first year of life. In hepatoblastoma, AFP rises abnormally. Regular AFP blood tests are therefore part of the surveillance plan for children with BWS during the hepatoblastoma risk period (broadly, the first three to four years of life). A rising AFP level — particularly one that rises out of the expected downward trend for the child’s age — can trigger earlier imaging even between scheduled scans. The AFP result is interpreted in context of the child’s age, not as an absolute number in isolation.
Review scan results with a multidisciplinary team — not just the radiologist
At CION, every surveillance scan result for a high-risk child is reviewed by a team that includes a paediatric oncologist, the radiologist who performed the scan, and, where indicated, a paediatric surgeon and a nephrologist or hepatologist. This matters because a kidney finding that looks reassuring on the radiologist’s report may warrant a different level of attention when viewed by an oncologist familiar with BWS-related Wilms tumour progression. The opposite is also true: an incidental finding that prompts anxiety in isolation can often be contextualised and monitored without immediate intervention. Multidisciplinary review means decisions are calibrated, not reactive.
Know when screening can be de-intensified — surveillance does not last forever
The cancer risk in BWS is highest in the first eight years of life. As children grow older and remain tumour-free, the surveillance schedule can be safely spread out and eventually discontinued according to published protocol timelines. The transition out of intensive surveillance is an important conversation to have with your child’s oncology and genetics teams — it should be based on the molecular subtype, the age at which the risk falls substantially, and the result of each previous scan. Knowing that there is a defined end point to the most intense part of surveillance helps many families manage the emotional demands of regular scanning over the early childhood years.
Act immediately if a lump or new symptom appears between scans
Surveillance scans are performed at defined intervals, but cancer does not follow a schedule. Parents of children with BWS should be aware of the warning signs that warrant an unscheduled medical assessment: a new lump or swelling in the abdomen or flank; blood in the urine, which may give the urine a pink, red, or smoky colour; a belly that appears to be growing larger on one or both sides; unexplained high blood pressure (which a child may show as irritability, headache, or unusual tiredness); or any symptom that feels out of the ordinary for your child. Bringing these to your oncology team’s attention promptly — rather than waiting for the next scheduled scan — is the right decision. No referral is ever wasted when a child has a known elevated cancer risk.
You are not alone in this
We walk this journey with you — from genetics to screening to care
A BWS diagnosis is a lot to take in. Our team will go through every report, every scan result, and every question with you — in a 45-minute consultation, not a rushed five-minute review.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Your questions about Beckwith-Wiedemann syndrome and cancer risk — answered
What is Beckwith-Wiedemann syndrome?
Beckwith-Wiedemann syndrome (BWS) is a growth-regulation disorder present from birth. It is caused by changes in a specific region of chromosome 11 that controls how cells grow and divide. Children with BWS are often larger than average at birth, may have organs that are bigger than expected (a condition called organomegaly), and sometimes have a slightly enlarged tongue (macroglossia), abdominal wall differences such as an umbilical hernia or omphalocele, or asymmetric overgrowth where one side of the body is larger than the other (hemihypertrophy or hemihyperplasia). Not all features are present in every child; BWS exists on a spectrum. The diagnosis is confirmed through clinical assessment and, where features are present, through molecular genetic testing of the chromosome 11 region.
Why does Beckwith-Wiedemann syndrome increase the risk of childhood cancer?
The chromosome 11 region affected in BWS (known as 11p15.5) contains genes that normally regulate cell growth and programme certain cells to stop dividing. When this regulation is disrupted — either because of how the DNA is chemically modified (epigenetic changes) or because of a direct change in the gene sequence — cells in certain organs can grow in an uncontrolled way. In the kidney, this predisposes to Wilms tumour (nephroblastoma). In the liver, it predisposes to hepatoblastoma. The tumours arise from the same growth-dysregulation that causes the physical features of BWS; they are not a coincidence. Identifying BWS means identifying this elevated cancer risk early, which is why structured screening is central to BWS management.
Which cancers are associated with Beckwith-Wiedemann syndrome?
The two cancers most strongly linked to BWS are Wilms tumour (a kidney cancer) and hepatoblastoma (a liver cancer). Both typically occur in young children, most often before the age of eight, and both are the reason that specialist surveillance programmes recommend regular abdominal ultrasound scans throughout early childhood for children with confirmed BWS. Wilms tumour is the more frequently seen of the two. Other tumours — including adrenocortical carcinoma, rhabdomyosarcoma, and certain other childhood solid tumours — have been reported in association with BWS, though these are less common. The overall elevated cancer risk is the reason that every child with BWS should be followed in a coordinated way by both a clinical genetics team and a paediatric oncology team.
How common is cancer in children with Beckwith-Wiedemann syndrome?
The cancer risk in BWS depends on the specific underlying molecular cause. Children with certain genetic subtypes of BWS — particularly those with paternal uniparental disomy of chromosome 11p15 or certain methylation changes at that locus — carry a meaningfully higher risk than the general population. Overall, published figures suggest that a minority of children with BWS will develop a tumour, but the risk is high enough to justify structured, protocol-driven surveillance across early childhood. Because the exact risk varies by molecular subtype, the cancer surveillance plan is individualised based on the genetic testing result. This is one reason why knowing the precise molecular cause of a child's BWS matters as much as the clinical diagnosis itself.
What does BWS cancer screening involve and how often does my child need to be scanned?
BWS cancer screening relies primarily on regular abdominal ultrasound examinations. Ultrasound can detect early Wilms tumour and hepatoblastoma before they cause symptoms, at a stage when treatment is more straightforward. Most published BWS surveillance guidelines recommend ultrasound every three to four months during the period of highest risk, which runs from birth through approximately age eight (for Wilms tumour) and up to about age three to four (for hepatoblastoma). The exact intervals and duration in your child's case will be guided by the molecular cause of BWS and by any additional features. Regular blood tests, including serum alpha-fetoprotein (AFP) measurement for hepatoblastoma risk, may also be part of the surveillance plan. Your child's team at CION co-ordinates these scans and reviews the results alongside the genetics and paediatric oncology teams.
What should I do if my child has been diagnosed with Beckwith-Wiedemann syndrome but has not yet seen a paediatric oncologist?
You should arrange a paediatric oncology review as early as possible — ideally within weeks of the BWS diagnosis, not months. A paediatric oncologist who works with high-risk children can confirm which surveillance protocol applies to your child's specific molecular subtype, arrange the first ultrasound and any blood tests needed, explain what findings would prompt further investigation, and help you understand the timeline. Having a clear, written surveillance schedule in hand means scans happen on time and results are reviewed promptly. At CION, we offer a dedicated high-risk child cancer surveillance pathway — your first consultation is free, and we will review your child's genetic reports, current imaging, and medical history to confirm the right protocol.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.